We have developed one of the most expansive, market-driven and differentiated portfolios of primary drug containers and advanced delivery systems in our industry for the administration of injectable therapies. Each of our device technologies has been developed in direct response to unmet or emerging market needs including the prevention of needlestick injuries, the efficient reconstitution of lyophilized drugs, the subcutaneous delivery of large volume doses, the intuitive self-injection of injectable therapies outside of healthcare facilities and the commercialization of novel pipeline drugs requiring specialized delivery systems. We can customize our device technology platforms to address specific customer, drug or patient requirements.
Our device portfolio is suitable for use with brand name, generic or biosimilar drugs and vaccines supplied in either a liquid stable or lyophilized format for delivery via administration routes including subcutaneous injection. Collaborations with pharmaceutical and biotechnology companies primarily relate to the use of our devices with late stage pipeline or marketed injectable therapies including biologics that are indicated, or being developed, for the treatment of a variety of acute and chronic conditions.
Our technology platforms cover the following device categories: